BioAge 在肝酶问题后停止肥胖药物试验;股票暴跌。 BioAge halts obesity drug trial after liver enzyme issues; stock plummets.

在一些参与者显示肝酶升高后,BioAge实验室已停止了对肥胖性药物Azelaplag的第二阶段试验。 BioAge Labs has halted its Phase 2 trial for the obesity drug azelaprag after some participants showed elevated liver enzymes. 使用Eli Lilly的tirzepatide(tirzepatide)进行药物单独测试。 The drug was being tested alone and with Eli Lilly’s tirzepatide. 在只有tirzepatide(tirzepatide)的团体中,没有出现任何问题的报道。 No issues were reported in the tirzepatide-only group. 2025年初,BioAge将分享更新后的青蛙计划。 BioAge will share updated plans for azelaprag in early 2025. 该公司的股价在宣布后超时交易中下跌了60%以上。 The company’s stock dropped over 60% in after-hours trading following the announcement.